Four separate in vivo experiments were conducted to replicate distinct tumor burdens (comprising low and high tumor burdens) (Figures 5A and 5E) and various tumor heterogeneity scenarios, involving BCMA+CD1d− MM tumor cells (Figures 5A and 5E), BCMA+CD1d+ MM tumor cells (Figure 5I), and BCMA−CD1d− MM tumor cells (Figure 5M). Here, TNFRSF17 is linked to Miyoshi myopathy.